Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Baodong Qin100 enrolled

Overview

This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.

All EGFR mutation NSCLC patients with EGFR-TKIs eventually develop acquired resistance and in 40%-50% of these the resistance mechanism is based on the EGFR T790M mutation who could receive Osimertinib. Several alternative mechanisms of escape from EGFR-TKIs have been detected in NSCLC patients without the T790M, such as Met application, BRAF mutation, PIK3CA mutation, etc, who could receive the combination of EGFR-TKI with comparable target drug. Given the lack of targeted therapy for the majority of T790M-negative patients, platinum-doublet chemotherapy remains the standard of care with low effectiveness. In the present study, we aimed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

NSCLC Stage IV EGFR T790M-negative Anlotinib JS001

Eligibility

Sex: ALLMin age: 18 MonthsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients \>=18 years of age * Inoperable locally advanced, recurrent, and/or metastatic NSCLC patients with EGFR sensitive mutation * EGFR-TKI resistent * EGFR T790M negative * Expected survival ≥ 3 month; * ECOG / PS score: 0-2; * the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL \<1.5 times the upper limit of normal (ULN); Liver ALT and AST \<2.5 × ULN and if liver metastases, ALT and AST \<5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min Exclusion Criteria: * EGFR-T790M positive * with druggable gene alteration; * Patient can not comply with research program requirements or follow-up;

Locations (1)

Shanghai Changzheng Hospital

Shanghai, China

RECRUITING

Outcomes

Primary Outcomes

Progression-Free Survival (PFS)

Time from treatment beginning until disease progression

Time frame: Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months

Objective Response Rate

Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission.

Time frame: Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months

Secondary Outcomes

Overall Survival

Time from treatment beginning until death from any cause

Time frame: From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months

Adverse Effect

Incidence of Treatment-related adverse Events

Time frame: Through study completion, an average of 1 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.